On January 6, 2020 Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions for diseases with high unmet medical need, reported it will present at the 38th Annual J.P. Morgan Healthcare Conference to be held January 13-16 in San Francisco, CA (Press release, Aeglea BioTherapeutics, JAN 6, 2020, View Source [SID1234552791]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Highlights: Aeglea will present on its strategic focus in developing innovative human enzyme therapeutics with defined potential to address Arginase 1 Deficiency, Homocystinuria and Cystinuria.
Date: Wednesday, January 15, 2020
Time: 2:30 p.m. PST; 5:30 p.m. EST
Presenter: Anthony G. Quinn, M.B. Ch.B., Ph.D., Aeglea’s president and chief executive officer
Location: Westin St. Francis Hotel, San Francisco, California
Webcast: View Source

To access the live and archived audio webcast, visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. Replays of the webcast will be available for 30 days thereafter.